Carolyn Magill Joins Define Ventures as Venture Partner in Health Tech

Carolyn Magill Appointed as Venture Partner at Define Ventures

Define Ventures has announced the appointment of Carolyn Magill as a venture partner starting March 11, 2025. Known for her substantial experience in the health tech sector, Carolyn is expected to significantly enhance innovation across various domains including providers, payers, and pharmaceuticals.

With a remarkable career spanning 25 years, Carolyn has previously served as the CEO of Aetion, a company that specializes in transforming real-world data into regulatory-grade evidence crucial for healthcare decisions. In addition to her role at Aetion, she has also been the CEO of Remedy Partners, a frontrunner in bundled payments software and services. Her diverse expertise is further emphasized by her position as Executive Vice President of Payer Strategy and Operations at Evolent Health, where she played an instrumental role in guiding the company from its startup phase to a successful IPO. Carolyn’s past leadership roles at UnitedHealth Group, particularly as COO of its Community and State plan in New Jersey, solidify her extensive background in healthcare management.

Lynne Chou O'Keefe, the founder and managing partner at Define Ventures, expressed confidence in Carolyn's capabilities, stating, "Carolyn's extensive experience across payer, provider, and pharmaceutical sectors makes her uniquely qualified to guide the next generation of health tech innovators." Her profound expertise in utilizing data and artificial intelligence within the pharmaceutical landscape stands to be highly beneficial for the firm’s partner companies.

In her own words, Carolyn remarked, "Define represents the best of venture — an incredible founder community and a team of experienced operators who truly understand what it takes to build in healthcare. Throughout my career, I've worked across many corners of healthcare, and joining Define allows me to bring that experience to the earliest stages of innovation, helping founders turn ideas into impact."

Carolyn’s appointment comes at a pivotal time for Define Ventures as the firm strives to bolster its capacity for partnership and foster the development of innovative health tech solutions. With established venture partners Bruce Broussard, former CEO of Humana, and Frank Williams, co-founder and former CEO of Evolent Health, Carolyn joins a prominent lineup of leaders who are set to augment Define's influence and effectiveness in the health tech sphere.

Currently managing $800 million in assets, Define Ventures primarily focuses on early-stage health tech companies, offering support to firms in seed, series A, and series B stages. The firm adopts a high conviction approach to entrepreneurship, working alongside notable companies like Hims & Hers, Unite Us, and Cohere Health. Their mission encapsulates a forward-thinking vision for healthcare, intertwined with a deep understanding of the industry supported by technology-driven methodologies.

Carolyn Magill's addition to Define Ventures not only strengthens the firm's leadership but also symbolizes a commitment to advancing health tech innovation. As the healthcare landscape rapidly evolves, the collaborative efforts of Carolyn and Define's existing partners will undoubtedly pave the way for substantial growth and groundbreaking solutions in the market.

For more information about Define Ventures, interested parties can visit www.definevc.com.